SCHEMBL2003153

SCHEMBL2003153

Cc1nc2cc([N+](=O)[O-])c(Oc3ccc(CC(=O)O)cc3Cl)cc2n1COCC[Si](C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 3/20 0.39
PPARA Q07869 2/20 0.39
PPARG P37231 2/20 0.39
DCTPP1 Q9H773 4/20 0.34
PTGDR2 Q9Y5Y4 2/20 0.34
PTGDR Q13258 1/20 0.34
HTT P42858 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
MAPT P10636 1/20 0.33
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
ALDH1A1 P00352 1/20 0.32
FFAR1 O14842 1/20 0.32
NPC1 O15118 1/20 0.32
JAK2 O60674 1/20 0.32
RAB9A P51151 1/20 0.32
HKDC1 Q2TB90 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3641599 1.00 PPARD (0.39) PPARDPPARAPPARGDCTPP1PTGDR2
SCHEMBL2008340 0.92 DCTPP1 (0.35) PPARDPPARAPPARGDCTPP1PTGDR2
SCHEMBL14819947 0.90 PPARD (0.38) PPARDPPARAPPARGDCTPP1PTGDR2
SCHEMBL2002775 0.79 DCTPP1 (0.35) PPARGDCTPP1MAPTMEN1KMT2A
SCHEMBL14819909 0.74 PPARD (0.40) PPARDPPARAPPARGPTGDR2PTGDR
SCHEMBL3673095 0.73 DCTPP1 (0.35) DCTPP1MEN1KMT2AALDH1A1NPC1
SCHEMBL2005624 0.72 PTGDR (0.46) PTGDR2PTGDR
SCHEMBL2004037 0.71 DCTPP1 (0.33) DCTPP1MEN1KMT2AALDH1A1NPC1
SCHEMBL29984952 0.69 MEN1 (0.46) SMN1; SMN2MAPTMEN1KMT2AALDH1A1
SCHEMBL12570878 0.69 DCTPP1 (0.34) PPARGDCTPP1MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2164828-B1 COMPOUNDS AS CRTH2 AND/OR PGD2 RECEPTORS MODULATORS AND THEIR USE FOR TREATING ASTHMA AND ALLERGIC INFLAMMATION AMGEN INC (US) 2013-03-27 EP disclosed
US-7960567-B2 Compounds and methods useful for treating asthma and allergic inflammation AMGEN INC. (US) 2011-06-14 US disclosed
US-7960567-B2 Compounds and methods useful for treating asthma and allergic inflammation AMGEN INC. (US) 2011-06-14 US disclosed
EP-2164828-A2 COMPOUNDS AS CRTH2 AND/OR PGD2 RECEPTORS MODULATORS AND THEIR USE FOR TREATING ASTHMA AND ALLERGIC INFLAMMATION Amgen Inc. (US) 2010-03-24 EP disclosed
US-20080312270-A1 COMPOUNDS AND METHODS USEFUL FOR TREATING ASTHMA AND ALLERGIC INFLAMMATION AMGEN INC. 2008-12-18 US disclosed
US-20080312270-A1 COMPOUNDS AND METHODS USEFUL FOR TREATING ASTHMA AND ALLERGIC INFLAMMATION AMGEN INC. 2008-12-18 US disclosed
WO-2008137027-A2 COMPOUNDS AS CRTH2 AND/OR PGD2 RECEPTORS MODULATORS AND THEIR USE FOR TREATING ASTHMA AND ALLERGIC INFLAMMATION AMGEN INC. (US) 2008-11-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312270-A1 COMPOUNDS AND METHODS USEFUL FOR TREATING ASTHMA AND ALLERGIC INFLAMMATION CCL11, LTC4S, TSLP PPARD 228/4885PPARA 281/4885PPARG 111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.